Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study

Abstract

To clarify the clinical features of adult patients with acute leukemia (AL) with 11q23 abnormalities, we performed a retrospective analysis of data from 58 adult Japanese patients: 51 with acute myeloid leukemia (AML), and 7 with acute lymphoblastic leukemia (ALL). The incidences according to fusion partners in AML were: t(9;11), 31.3%; t(11;19), 27.4%; t(6;11), 21.5%. The incidence of patients with t(11;19) was higher than those in the US and Europe, and the incidence of t(4;11) was lower than that in childhood. The results indicated the poor prognosis of AML with 11q23 abnormalities regardless of the fusion partners. AML patients with 11q23 aged <60 years in the first CR who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed a more favorable outcome than those treated without allo-HSCT, although the differences were not statistically significant (P = 0.322 for DFS, P = 0.138 for OS). This result suggests that treatment strategies including allo-HSCT may be considered in the first CR in cases of AML with 11q23 abnormalities. However, further studies involving a large number of cases are required to assess the effect of allo-HSCT on adult AL with 11q23 abnormalities.

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

“…However, t(11;19) was also identified as an independent adverse prognostic feature in adult AML, a finding that is consistent with the results reported in the majority of other such studies 16, 17, 25 but that conflicts with the findings of a recent study by the Medical Research Council. 4 …”

Rearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase II

“…The frequency of MLL gene rearrangement in Japanese adult t-AML was (27.4%) [16] and higher than was reported to be about 5–10% in Caucasian populations [17,18], with different frequency from different European countries from 5 to 15% [19,20,21]. This difference may be due in part to the lack of attention to t-MDS, which focused on primary MDS and t-AML, also due to different numbers of patients involved in different studies.…”

11q23/MLL Acute Leukemia : Update of Clinical Aspects

“…30 In a previous study in a population of adult Japanese patients, the 1-year EFS was 22.2% and the 2-year OS was 33.7%, indicating a similarly poor prognosis to that in the CALGB study. 43 The prognosis of children with AML with t(6;11) (p27;q23) is also very poor. The results of an international retrospective study performed in 2009 indicated a 5-year OS and EFS of patients with t(6;11) (p27;q23) of 22% and 11%, respectively.…”